share_log

Guggenheim Initiates Coverage On Medicenna Therapeutics With Buy Rating, Announces Price Target of C$2

Benzinga Real-time News ·  Nov 29, 2022 20:56

Guggenheim analyst Charles Zhu initiates coverage on Medicenna Therapeutics (TSX:MDNA) with a Buy rating and announces Price Target of C$2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment